Peptide Cycling Protocols: BPC-157, Ipamorelin, TB-500

What peptide cycling means

Peptide cycling is the practice of taking a peptide for a defined period, then stopping for a washout window before resuming or moving on to another agent. The rationale draws on two ideas. The first is receptor desensitization: continuous exposure to certain peptides may downregulate the receptors they act on, reducing effect over time. The second is risk management: shorter exposures with breaks may produce a different long-term safety profile than continuous use, though the evidence base for this in peptides specifically is thin.

The peptides discussed here (BPC-157, the growth-hormone secretagogues like ipamorelin and CJC-1295, and TB-500, the thymosin beta-4 fragment) are not FDA-approved for any indication. They are sold as research chemicals or compounded from unregulated suppliers in much of the world. This article describes cycling patterns that circulate in the literature and community discussions; it is not an endorsement.

The regulatory picture first

Most peptides in the wellness and recovery space exist in a regulatory gray zone. BPC-157, body protection compound, is a synthetic pentadecapeptide derived from a sequence in human gastric juice. It has substantial animal research and minimal human clinical research. The FDA has explicitly placed BPC-157 on the Category 2 bulk substances list, citing significant safety risks. Compounding pharmacies in the United States that work with it after late 2023 are operating against FDA guidance.

TB-500, often marketed as the active fragment of thymosin beta-4, has similar status. Ipamorelin, CJC-1295, and other growth-hormone secretagogues sit in a comparable position. The published animal data are interesting; the human data are sparse and largely uncontrolled.

This means the cycling protocols described below are not standardized by any regulatory body. They are patterns assembled from the bodybuilding and biohacking community, occasional clinical case reports, and the extrapolation of animal study durations.

BPC-157 cycle patterns

Reported community protocols for BPC-157 typically run four to eight weeks of daily administration followed by a washout of two to four weeks. The rationale offered for cycling is largely precautionary; there is no clear receptor desensitization mechanism for BPC-157 because its receptor target is not fully characterized.

A common pattern is a four-week cycle targeted around a specific injury or recovery goal, followed by an equal washout, and then either a repeat cycle if the issue persists or discontinuation. Some users run longer continuous courses; others use it episodically only during acute injury recovery.

The route of administration varies. Subcutaneous injection near the site of injury is the most commonly reported route. Oral preparations exist but the bioavailability is uncertain because BPC-157 is a peptide subject to gastric degradation.

Growth-hormone secretagogue cycles

Ipamorelin, CJC-1295, GHRP-2, and similar peptides stimulate endogenous growth hormone release through the pituitary. The community-reported cycling rationale here is more grounded than for BPC-157: continuous stimulation of the GH axis plausibly produces some degree of pituitary down-regulation.

Typical protocols run eight to twelve weeks on, followed by a washout of four weeks before resuming. The reasoning is to allow the GH axis to return to baseline responsiveness. Cycle length is influenced by the half-life of the specific peptide; CJC-1295 with DAC (a longer-acting version) is often run on different schedules than the shorter-acting ipamorelin.

Stacking growth-hormone secretagogues with each other (a "GHRH + GHRP" combination like CJC-1295 + ipamorelin) is common in community protocols because the two classes act on different receptors and the GH release is reportedly synergistic. Stacking with TB-500 or BPC-157 is also reported, on the theory that the mechanisms are independent.

TB-500 cycle patterns

TB-500 cycles in community protocols typically run four to six weeks at a loading frequency (twice weekly), followed by a maintenance phase or full washout. The pattern mirrors what is reported in veterinary use, where thymosin beta-4 has been used for tendon injuries in racehorses.

Washout periods of four to eight weeks between TB-500 cycles are common. Some users run only a single cycle for a specific injury and do not repeat.

What stacking actually means

Stacking is the simultaneous use of two or more peptides on the theory that the effects are complementary. A frequently discussed stack is BPC-157 plus TB-500 for soft tissue injury, on the rationale that they target somewhat different aspects of tissue repair (vascular versus structural). Whether the combination produces results superior to either alone in humans is unestablished.

Stacking also stacks risk. Each agent independently has an uncertain long-term safety profile. The combined effects are even less well characterized.

What is not known

The long-term safety of any of these peptides in humans is unknown. The cancer risk question, particularly for growth-hormone secretagogues given the relationship between IGF-1 elevation and certain cancers, is unresolved and frequently glossed over in community discussions. The cardiovascular effects, immune effects, and effects on endocrine axes over years of intermittent use are not characterized.

The supply chain is its own variable. Peptides sold as research chemicals are not subject to the same purity controls as pharmaceuticals. Independent testing of peptides purchased from various online vendors has found significant variation in actual content versus labeled content, and contamination is documented.

When to seek medical advice

The honest framing is that this entire category sits outside the standard medical evidence base. A clinician experienced in regenerative or integrative medicine can sometimes provide oversight, but most physicians have neither the training nor the legal cover to prescribe these. Self-administration of peptides sourced from unregulated suppliers carries risks that the cycling protocols above do not address: contamination, dose inaccuracy, and the cumulative uncertainty of long-term effects.

Severe injection-site reactions, signs of infection, unexpected systemic symptoms, severe headache, vision changes, or any signs of an endocrine disturbance warrant immediate medical attention. Disclosing peptide use to clinicians, even when the conversation feels awkward, is important for accurate diagnosis if something goes wrong.

---

Wegovy®, Ozempic®, Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® are trademarks of Eli Lilly and Company. PepAI is independent.